Altmetric

Fungal genomics in respiratory medicine: what, how and when?

File Description SizeFormat 
Brackin2021_Article_FungalGenomicsInRespiratoryMed.pdfPublished version672.52 kBAdobe PDFView/Open
Title: Fungal genomics in respiratory medicine: what, how and when?
Authors: Brackin, A
Hemmings, S
Fisher, M
Rhodes, J
Item Type: Journal Article
Abstract: Respiratory infections caused by fungal pathogens present a growing global healthconcern and are a major cause of death in immunocompromised patients. Worryingly,coronavirus disease-19 (COVID-19) resulting in acute respiratory distress syndrome,has been shown to predispose some patients to fungal co-infection and secondarypulmonary aspergillosis. Aspergillosis is most commonly caused by the fungalpathogen Aspergillus fumigatus and primarily treated using the triazole drug group,however in recent years, this fungus has been rapidly gaining resistance against theseantifungals. This is of serious clinical concern as multi-azole resistant forms ofaspergillosis have a higher risk of mortality when compared against azole-susceptibleinfections. With the increasing numbers of COVID-19 and other classes ofimmunocompromised patients, early diagnosis of fungal infections is critical to ensuringpatient survival. However, time-limited diagnosis is difficult to achieve with currentculture-based methods. Advances within fungal genomics have enabled moleculardiagnostic methods to become a fast, reproducible, and cost-effective alternative fordiagnosis of respiratory fungal pathogens and detection of antifungal resistance. Herewe describe what techniques are currently available within molecular diagnostics, howthey work and when they have been used.
Issue Date: 7-Sep-2021
Date of Acceptance: 14-Jun-2021
URI: http://hdl.handle.net/10044/1/91386
DOI: 10.1007/s11046-021-00573-x
ISSN: 0301-486X
Publisher: Springer
Start Page: 589
End Page: 608
Journal / Book Title: Mycopathologia
Volume: 186
Copyright Statement: © The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Sponsor/Funder: Wellcome Trust
Medical Research Council (MRC)
Funder's Grant Number: 219551/Z/19/Z
MR/R015600/1
Keywords: Science & Technology
Life Sciences & Biomedicine
Mycology
Mycoses
Genomics
Aspergillus fumigatus
Respiratory diseases
MEDIATED ISOTHERMAL AMPLIFICATION
INVASIVE PULMONARY ASPERGILLOSIS
POLYMERASE-CHAIN-REACTION
IN-VITRO ACTIVITY
REAL-TIME PCR
EXOPHIALA-DERMATITIDIS
PNEUMOCYSTIS-JIROVECII
CYSTIC-FIBROSIS
ANTIFUNGAL SUSCEPTIBILITY
WANGIELLA DERMATITIDIS
Aspergillus fumigatus
Genomics
Mycoses
Respiratory diseases
Aspergillus fumigatus
COVID-19
Genomics
Humans
Pulmonary Medicine
SARS-CoV-2
Microbiology
0607 Plant Biology
Publication Status: Published
Online Publication Date: 2021-09-07
Appears in Collections:Faculty of Medicine
School of Public Health



This item is licensed under a Creative Commons License Creative Commons